lactulose
Selected indexed studies
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (PLoS One, 2022) [PMID:35471992]
- Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. (Hepatol Commun, 2024) [PMID:38727685]
- Lactulose: Patient- and dose-dependent prebiotic properties in humans. (Anaerobe, 2019) [PMID:31176002]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Combination therapy with rifaximin and lactulose in hepatic encephalopathy: A systematic review and meta-analysis. (2022) pubmed
- Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. (2024) pubmed
- Lactulose: Patient- and dose-dependent prebiotic properties in humans. (2019) pubmed
- Lactulose production from lactose isomerization by chemo-catalysts and enzymes: Current status and future perspectives. (2022) pubmed
- Lactulose: A Simple Sugar in a Complex Encephalopathy. (2018) pubmed
- A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. (2013) pubmed
- Lactulose--a multifaceted substance. (1997) pubmed
- Lactulose: production, purification and potential applications. (2011) pubmed
- The potential role of lactulose pharmacotherapy in the treatment and prevention of diabetes. (2022) pubmed
- Lactulose, disaccharides and colonic flora. Clinical consequences. (1997) pubmed